Cargando…

Phenotypic clusters and survival analyses in interstitial pneumonia with myositis-specific autoantibodies

BACKGROUND: Idiopathic inflammatory myopathy (IIM) is highly combined with interstitial pneumonia (IP), often as the initial or solo presentation with positive myositis-specific autoantibodies (MSAs) but does not fulfill the diagnostic criteria. OBJECTIVES: We aimed to explore the phenotypic cluster...

Descripción completa

Detalles Bibliográficos
Autores principales: Lia, Yihua, Fana, Yali, Wanga, Yuanying, Yanga, Shuqiao, Dua, Xuqin, Yea, Qiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787374/
https://www.ncbi.nlm.nih.gov/pubmed/35115753
http://dx.doi.org/10.36141/svdld.v38i4.11368
_version_ 1784639349792440320
author Lia, Yihua
Fana, Yali
Wanga, Yuanying
Yanga, Shuqiao
Dua, Xuqin
Yea, Qiao
author_facet Lia, Yihua
Fana, Yali
Wanga, Yuanying
Yanga, Shuqiao
Dua, Xuqin
Yea, Qiao
author_sort Lia, Yihua
collection PubMed
description BACKGROUND: Idiopathic inflammatory myopathy (IIM) is highly combined with interstitial pneumonia (IP), often as the initial or solo presentation with positive myositis-specific autoantibodies (MSAs) but does not fulfill the diagnostic criteria. OBJECTIVES: We aimed to explore the phenotypic clusters and prognosis of the patients with IP and positive MSA, which is called MSA-IP in the present study. METHODS: A total of 178 patients with MSA-IP were prospectively enrolled for analysis. Serum MSAs were detected using Western blotting. Radiological patterns of IP were determined according to the classification of idiopathic IPs. Clusters of patients with MSA-IP were identified using cluster analysis. Predictors for acute/subacute onset, therapeutic response, IP progression and survival were also analyzed. RESULTS: Patients with MSA-IP were classified into four distinct clusters. Cluster 1 were the elderly with chronic onset, nearly normal oxygenation and good survival. Cluster 2 had dyspnea on exertion and nonspecific IP pattern, with moderate survival. Patients in cluster 3 had chronic onset and were prone to IP progression (OR 2.885). Cluster 4 had multi-systemic involvements, positive anti-melanoma differentiation associated gene 5 antibody, and were prone to acute/subacute onset (OR 3.538) and IP progression (OR 5.472), with poor survival. Corticosteroids combined immunosuppressants showed therapeutic response in MSA-IP (OR 4.303) and had a protective effect on IP progression (OR 0.136). CONCLUSIONS: Four clusters of the patients with MSA-IP suggested the distinct clinical, radiological and prognostic features.
format Online
Article
Text
id pubmed-8787374
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Mattioli 1885
record_format MEDLINE/PubMed
spelling pubmed-87873742022-02-02 Phenotypic clusters and survival analyses in interstitial pneumonia with myositis-specific autoantibodies Lia, Yihua Fana, Yali Wanga, Yuanying Yanga, Shuqiao Dua, Xuqin Yea, Qiao Sarcoidosis Vasc Diffuse Lung Dis Original Article: Clinical Research BACKGROUND: Idiopathic inflammatory myopathy (IIM) is highly combined with interstitial pneumonia (IP), often as the initial or solo presentation with positive myositis-specific autoantibodies (MSAs) but does not fulfill the diagnostic criteria. OBJECTIVES: We aimed to explore the phenotypic clusters and prognosis of the patients with IP and positive MSA, which is called MSA-IP in the present study. METHODS: A total of 178 patients with MSA-IP were prospectively enrolled for analysis. Serum MSAs were detected using Western blotting. Radiological patterns of IP were determined according to the classification of idiopathic IPs. Clusters of patients with MSA-IP were identified using cluster analysis. Predictors for acute/subacute onset, therapeutic response, IP progression and survival were also analyzed. RESULTS: Patients with MSA-IP were classified into four distinct clusters. Cluster 1 were the elderly with chronic onset, nearly normal oxygenation and good survival. Cluster 2 had dyspnea on exertion and nonspecific IP pattern, with moderate survival. Patients in cluster 3 had chronic onset and were prone to IP progression (OR 2.885). Cluster 4 had multi-systemic involvements, positive anti-melanoma differentiation associated gene 5 antibody, and were prone to acute/subacute onset (OR 3.538) and IP progression (OR 5.472), with poor survival. Corticosteroids combined immunosuppressants showed therapeutic response in MSA-IP (OR 4.303) and had a protective effect on IP progression (OR 0.136). CONCLUSIONS: Four clusters of the patients with MSA-IP suggested the distinct clinical, radiological and prognostic features. Mattioli 1885 2021 2021-12-31 /pmc/articles/PMC8787374/ /pubmed/35115753 http://dx.doi.org/10.36141/svdld.v38i4.11368 Text en Copyright: © 2021 SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License
spellingShingle Original Article: Clinical Research
Lia, Yihua
Fana, Yali
Wanga, Yuanying
Yanga, Shuqiao
Dua, Xuqin
Yea, Qiao
Phenotypic clusters and survival analyses in interstitial pneumonia with myositis-specific autoantibodies
title Phenotypic clusters and survival analyses in interstitial pneumonia with myositis-specific autoantibodies
title_full Phenotypic clusters and survival analyses in interstitial pneumonia with myositis-specific autoantibodies
title_fullStr Phenotypic clusters and survival analyses in interstitial pneumonia with myositis-specific autoantibodies
title_full_unstemmed Phenotypic clusters and survival analyses in interstitial pneumonia with myositis-specific autoantibodies
title_short Phenotypic clusters and survival analyses in interstitial pneumonia with myositis-specific autoantibodies
title_sort phenotypic clusters and survival analyses in interstitial pneumonia with myositis-specific autoantibodies
topic Original Article: Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787374/
https://www.ncbi.nlm.nih.gov/pubmed/35115753
http://dx.doi.org/10.36141/svdld.v38i4.11368
work_keys_str_mv AT liayihua phenotypicclustersandsurvivalanalysesininterstitialpneumoniawithmyositisspecificautoantibodies
AT fanayali phenotypicclustersandsurvivalanalysesininterstitialpneumoniawithmyositisspecificautoantibodies
AT wangayuanying phenotypicclustersandsurvivalanalysesininterstitialpneumoniawithmyositisspecificautoantibodies
AT yangashuqiao phenotypicclustersandsurvivalanalysesininterstitialpneumoniawithmyositisspecificautoantibodies
AT duaxuqin phenotypicclustersandsurvivalanalysesininterstitialpneumoniawithmyositisspecificautoantibodies
AT yeaqiao phenotypicclustersandsurvivalanalysesininterstitialpneumoniawithmyositisspecificautoantibodies